simvastatin has been researched along with Myeloproliferative Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanc-Brude, O; Boulanger, CM; Camara, F; Dagher, T; Davy, H; Devue, C; Dingli, F; El Mdawar, MB; Hatem, SN; James, C; Kheloufi, M; Lasselin, J; Loew, D; Merchant, S; Mougenot, N; Plessier, A; Poisson, J; Rautou, PE; Souyri, M; Tanguy, M; Villeval, JL | 1 |
| Griner, LN; Johnson, JO; List, AF; McGraw, KL; Reuther, GW | 1 |
2 other study(ies) available for simvastatin and Myeloproliferative Disorders
| Article | Year |
|---|---|
Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm.
Topics: Animals; Antioxidants; Aorta, Thoracic; Cardiovascular Diseases; Cell-Derived Microparticles; Erythrocytes; Femoral Artery; Gain of Function Mutation; Humans; In Vitro Techniques; Janus Kinase 2; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Oxidative Stress; Simvastatin; Vasoconstriction | 2020 |
JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth.
Topics: Apoptosis; beta-Cyclodextrins; Cell Line, Tumor; Cells, Cultured; Cholesterol; Colony-Forming Units Assay; Drug Evaluation, Preclinical; Erythroid Precursor Cells; Humans; Janus Kinase 2; K562 Cells; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Megakaryocyte Progenitor Cells; Membrane Lipids; Membrane Microdomains; Mutation, Missense; Myeloproliferative Disorders; Phosphorylation; Point Mutation; Protein Processing, Post-Translational; Signal Transduction; Simvastatin; STAT5 Transcription Factor | 2013 |